Hjem › Syndrom med oblitererende bronkiolitt › Massachusetts › Boston
Kliniske studier for Syndrom med oblitererende bronkiolitt i Boston, MA
13 studier for Syndrom med oblitererende bronkiolitt søker deltakere på steder i og rundt Boston (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
Axatilimab for Sclerotic Chronic Graft-versus-Host Disease
RekruttererFase 2
- Dana-Farber Cancer Institute, Boston
A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)
RekruttererFase 2
- Dana-Farber Cancer Institute- Site Number : 8400007, Boston
Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease
RekruttererFase 2
- Dana-Farber Cancer Institute, Boston
A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
RekruttererFase 3
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease
RekruttererObservasjonsstudie
- Massachusetts Cancer Research Center, Boston
Ex Vivo-Expanded Regulatory T Cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic GVHD
RekruttererFase 1
- Dana-Farber Cancer Institute, Boston
Plasma and Radiologic Biomarkers of Response to ECP in Lung Transplant Recipients With CLAD
RekruttererObservasjonsstudie
- Massachusetts General Hospital, Boston
- Brigham and Women's Hospital, Boston
A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)
RekruttererFase 2
- Massachusetts General Hospital, Boston
BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)
RekruttererFase 2
- Dana-Farber Cancer Institute, Boston
- Boston Children's Hospital, Boston
- Brigham and Women's Hospital, Boston
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
RekruttererFase 3
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Impact of Exercise on the Complications of Corticosteroids in Patients With GVHD: the RESTART Trial
Rekrutterer
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
RekruttererFase 2
- Dana-Farber Cancer Institute, Boston
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
RekruttererFase 1
- Dana-Farber Cancer Institute, Boston
Syndrom med oblitererende bronkiolitt-studier i andre byer
- Seattle, WA11 studier
- Atlanta, GA10 studier
- New York City, NY9 studier
- Houston, TX8 studier
- Los Angeles, CA7 studier
- Miami, FL7 studier
- Durham, NC6 studier
- Baldwin Park, CA6 studier
- Tampa, FL6 studier
- Philadelphia, PA6 studier
- Washington, DC6 studier
- San Francisco, CA5 studier
Andre studier i Boston
- Brystkreft112 studier
- Ikke-småcellet lungekreft90 studier
- Kreft (alle typer)85 studier
- Metastatisk kreft63 studier
- Kolorektal kreft63 studier
- Lungekreft62 studier
- Eggstokkreft61 studier
- Prostatakreft59 studier
- Depresjon52 studier
- Endometriekreft50 studier
- Hjertesvikt44 studier
- Akut myelogen leukemi44 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.